FTPP, fat-targeted proapoptotic peptide, Prohibitin-TP01, prohibitin-targeting peptide 1
A two-part synthetic peptide: one half homes to prohibitin, a protein on the lining of blood vessels that feed white fat, and the other half kills the cell it is delivered to. Starving fat tissue of its blood supply made obese animals lose fat quickly.
None of these uses is approved. Uses tested in people come first, then claims that rest on animal studies or user reports.
Trial: tested in people, with the result. Animal: cell or animal studies only.
Every compound’s uses, by body system: evidence map, and by condition: conditions A to Z.
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status outside the US checked October 7, 2026 against EMA, MHRA, Health Canada and TGA records. By country: EU, UK, Canada, Australia. Status of every compound.
Adipotide has two halves. The first, a nine-amino-acid loop, sticks to prohibitin, a protein found on the lining cells of blood vessels that feed white fat. The second is a short mirror-image sequence that breaks up the membranes of mitochondria, the cell’s power packs, and kills whatever cell it is carried into. In obese mice and monkeys, killing those vessel cells made white fat shrink, and blood sugar control improved.
AnimalMainly from cell and animal studies; not shown in people.
Why the fat is lost is disputed: treated monkeys ate less, and a letter in the same journal argued reduced food intake, not fat-vessel killing, explained the weight loss. Nothing about the mechanism has been shown in people.
NCT01262664
0.03 mg per kg under the skin once daily for 28 days was the opening dose of a dose-finding trial in men with metastatic prostate cancer. It was stopped after 4 patients and no tolerated dose was ever established.
No established dose exists. Figures quoted online disagree by more than tenfold and none comes from a human study. Monkey doses can’t be scaled to people, and the monkey kidney damage was dose-dependent.
No set cycle, shown over 26 weeks
The ways Adipotide is most often run, each tagged with where it comes from.
Men with metastatic prostate cancer and obesity, in hospital. Up to 5 dose levels were planned; the trial stopped after 4 patients and nothing was published.
Animal dose, not a human one. At this dose monkeys lost 7.4–14.7% of body weight, and creatinine rose above 0.25 mg per kg.
No human study supports any amount or schedule. The compound damaged monkey kidneys at the doses that worked.
0.03 mg/kg. The opening dose of the terminated phase 1 trial in men with metastatic prostate cancer and obesity (NCT01262664). No tolerated dose was ever established, and no result was published.
Injection under the skin in both the monkey studies and the human trial, given daily by trial staff with blood and urine tests throughout.
No published guidance, and no established schedule to miss a dose from.
Body weight fell 7.4–14.7% against +1.0 to −3.5% in untreated monkeys; BMI fell 3.7–17.3%; waist measurement fell 6.5–14.3% in 9 of 10.
AnimalTotal body fat on DEXA scans fell by about 39% on average, against about 15% in the untreated group, and kept falling for 3 weeks after the last injection.
AnimalA measure of insulin resistance fell by about 49% in treated monkeys while rising about 34% in the untreated group.
AnimalNothing is known. The only human trial was terminated after 4 patients and never reported weight, safety or anything else.
TrialKidney tubule damage and rising creatinine (monkeys, dose-dependent above 0.25 mg per kg)
Also sugar and protein in the urine. Mostly reversed within 28 days of stopping. No human data; nobody is checking an unsupervised user’s kidneys.
Passing more urine and mild dehydration (monkeys, highest doses)
Seen alongside the kidney changes.
Eating less, possibly from nausea (monkeys)
The study authors couldn’t rule out mild nausea as part of the weight loss.
Unknown in people
Four patients received it in a trial that reported nothing, so human side effects and their rates are unknown.
Injection-site pain, redness or infection (unregulated vials)
Use sterile technique. Spreading redness, heat or pus needs medical care.
Passing much less urine, swelling, confusion or breathlessness can mean kidney failure: stop and get medical help the same day. Hives with face or throat swelling or trouble breathing is an emergency.
The side effects people ask about most, answered one by one. Each answer says where it comes from.
Precaution: a concern that follows from how it works or from a related drug, not measured. Animal: seen only in animal studies. No data: no human safety data. A side effect that hasn’t been reported can still happen, especially with long or high-dose use. Any of these across every compound: the side-effect finder.
No product label covers adipotide, so these come from human studies and from precautions based on how it works. Most important first.
Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition. Every documented interaction, by medicine: drug interactions.
What’s known about pregnancy, breastfeeding, kidney and liver problems, age and surgery. Where nothing has been studied, the row says so.
Precaution: not studied, so the caution follows from how it works or from a related drug. Animal: from animal studies only. Ages are given as approved or studied; this site never gives doses for children. Across every compound: pregnancy, breastfeeding, kidney disease, liver disease, older adults and surgery.
Usually run on its own.
No published human studies of adipotide turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.
Registered trials that are still running, or that finished without published results, most important first. Checked on ClinicalTrials.gov, October 7, 2026.
First-in-human dose-finding in men with metastatic prostate cancer and obesity, with weight change as a secondary measure
Terminated at the investigator’s request; 4 of up to 15 planned patients enrolled, closed out January 2019, no results posted
Every compound’s registered trials: trials under way.
No human result has ever been published. The one trial enrolled 4 of up to 15 planned patients, all men with metastatic prostate cancer and obesity, and was terminated at the investigator’s request. Everything else is mice, rats and small groups of monkeys: 10 treated animals in the main 4-week study, with kidney damage at the effective dose and weight loss that may have come from eating less. Nothing is known about longer use, about healthy people, or about what is in an unregulated vial.
Sold as powder vials of unregulated research chemical. Strengths differ between sellers and nothing checks them. Vial Guide gives no mixing or dose figures: no tolerated human dose was ever established, and the dose that worked in monkeys also damaged their kidneys.
Every compound side by side: the half-life chart and the storage chart.
Every compound’s numbers: the identifiers table.
Half the molecule is built from mirror-image (D) amino acids, so the body cannot easily break it down. The homing half is a loop closed between its two cysteines; PubChem records the open form. Nothing regulates identity, purity or sterility.
A two-part synthetic peptide: one half homes to prohibitin, a protein on the lining of blood vessels that feed white fat, and the other half kills the cell it is delivered to. Starving fat tissue of its blood supply made obese animals lose fat quickly.
Adipotide has two halves. The first, a nine-amino-acid loop, sticks to prohibitin, a protein found on the lining cells of blood vessels that feed white fat. The second is a short mirror-image sequence that breaks up the membranes of mitochondria, the cell’s power packs, and kills whatever cell it is carried into. In obese mice and monkeys, killing those vessel cells made white fat shrink, and blood sugar control improved. Why the fat is lost is disputed: treated monkeys ate less, and a letter in the same journal argued reduced food intake, not fat-vessel killing, explained the weight loss. Nothing about the mechanism has been shown in people.
Not approved as a drug in the US, the EU or anywhere else. Its first-in-human trial, run at a US cancer center from 2012, was terminated at the investigator’s request and closed out in January 2019; no later trial has been registered. Never nominated for pharmacy compounding, so it appears on none of FDA’s 503A or 503B bulk substance category lists (503A list updated May 14, 2026).
From human studies (NCT01262664): 0.03 mg per kg under the skin once daily for 28 days was the opening dose of a dose-finding trial in men with metastatic prostate cancer. It was stopped after 4 patients and no tolerated dose was ever established. From community reports, not established: No established dose exists. Figures quoted online disagree by more than tenfold and none comes from a human study. Monkey doses can’t be scaled to people, and the monkey kidney damage was dose-dependent. These are the amounts sources reference, not recommendations.
No product label covers adipotide, so these come from human studies and from precautions based on how it works. Anyone with kidney disease: The kidney was the organ damaged in monkeys: creatinine rose, sugar and protein appeared in the urine and the tubules were injured, more so at higher doses. Anyone taking drugs that strain the kidneys: Adding a compound that injured monkey kidneys to drugs handled by the same organ has never been studied, in any species. Pregnancy or breastfeeding: No human safety data exist, and the compound is designed to kill blood-vessel cells, which a pregnancy depends on. The “Who should avoid it” section lists 2 more groups.
Before mixing: Freezer (−20 °C) for long-term storage, kept dry and dark. After mixing: Fridge (2–8 °C) once in solution. The monkey studies and the human trial used it dissolved in sterile saline. This is common practice; no product label covers it.
Probably. Not named in the 2026 List and not covered by a named section. An unapproved compound whose development stopped falls under S0 non-approved substances, banned at all times.
No published human studies turned up in our October 2026 review. The evidence note at the top of this page sums up what is known.
Trial 28 days of daily injections, in monkeys and in the terminated 4-patient trial. No human result was published.
Animal Injection under the skin in every study and in the terminated trial. No oral, nasal or skin form has been tested, and the molecule is a peptide that the gut would break down.
Precaution No data. No study has looked at the two together; both alcohol and dehydration add to kidney strain.
Precaution No study has combined them. Both lower appetite and body weight in animals or people, so effects could add up, including on dehydration.
Animal No label and no human overdose data. In monkeys, single doses far above the studied dose weren’t fatal, but kidney injury was dose-dependent. Call Poison Help (1-800-222-1222), or emergency services for severe symptoms.
For the protocol details
For uses, the side-effect questions, special situations, trials, identifiers and status outside the US
Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.